Corticobasal degeneration

Gerard M. Saranza, Jennifer L. Whitwell, Gabor G. Kovacs, Anthony E. Lang

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Corticobasal degeneration (CBD) is a rare neurodegenerative disease characterized by the predominance of pathological 4 repeat tau deposition in various cell types and anatomical regions. Corticobasal syndrome (CBS) is one of the clinical phenotypes associated with CBD pathology, manifesting as a progressive asymmetric akinetic-rigid, poorly levodopa-responsive parkinsonism, with cerebral cortical dysfunction. CBD can manifest as several clinical phenotypes, and similarly, CBS can also have a pathologic diagnosis other than CBD. This chapter discusses the clinical manifestations of pathologically confirmed CBD cases, the current diagnostic criteria, as well as the pathologic and neuroimaging findings of CBD/CBS. At present, therapeutic options for CBD remain symptomatic. Further research is needed to improve the clinical diagnosis of CBD, as well as studies on disease-modifying therapies for this relentlessly progressive neurodegenerative disorder.

Original languageEnglish (US)
Title of host publicationInternational Review of Neurobiology
EditorsMaria Stamelou, Günter U. Höglinger
PublisherAcademic Press Inc.
Pages87-136
Number of pages50
ISBN (Print)9780128177303
DOIs
StatePublished - 2019

Publication series

NameInternational Review of Neurobiology
Volume149
ISSN (Print)0074-7742
ISSN (Electronic)2162-5514

Fingerprint

Neurodegenerative Diseases
Phenotype
Parkinsonian Disorders
Levodopa
Rare Diseases
Neuroimaging
Pathology
Therapeutics
Research

Keywords

  • 4R-tauopathy
  • Atypical parkinsonism
  • Corticobasal degeneration
  • Corticobasal syndrome
  • Tauopathy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Saranza, G. M., Whitwell, J. L., Kovacs, G. G., & Lang, A. E. (2019). Corticobasal degeneration. In M. Stamelou, & G. U. Höglinger (Eds.), International Review of Neurobiology (pp. 87-136). (International Review of Neurobiology; Vol. 149). Academic Press Inc.. https://doi.org/10.1016/bs.irn.2019.10.014

Corticobasal degeneration. / Saranza, Gerard M.; Whitwell, Jennifer L.; Kovacs, Gabor G.; Lang, Anthony E.

International Review of Neurobiology. ed. / Maria Stamelou; Günter U. Höglinger. Academic Press Inc., 2019. p. 87-136 (International Review of Neurobiology; Vol. 149).

Research output: Chapter in Book/Report/Conference proceedingChapter

Saranza, GM, Whitwell, JL, Kovacs, GG & Lang, AE 2019, Corticobasal degeneration. in M Stamelou & GU Höglinger (eds), International Review of Neurobiology. International Review of Neurobiology, vol. 149, Academic Press Inc., pp. 87-136. https://doi.org/10.1016/bs.irn.2019.10.014
Saranza GM, Whitwell JL, Kovacs GG, Lang AE. Corticobasal degeneration. In Stamelou M, Höglinger GU, editors, International Review of Neurobiology. Academic Press Inc. 2019. p. 87-136. (International Review of Neurobiology). https://doi.org/10.1016/bs.irn.2019.10.014
Saranza, Gerard M. ; Whitwell, Jennifer L. ; Kovacs, Gabor G. ; Lang, Anthony E. / Corticobasal degeneration. International Review of Neurobiology. editor / Maria Stamelou ; Günter U. Höglinger. Academic Press Inc., 2019. pp. 87-136 (International Review of Neurobiology).
@inbook{cb0b30baca114d61b032d6995c40f964,
title = "Corticobasal degeneration",
abstract = "Corticobasal degeneration (CBD) is a rare neurodegenerative disease characterized by the predominance of pathological 4 repeat tau deposition in various cell types and anatomical regions. Corticobasal syndrome (CBS) is one of the clinical phenotypes associated with CBD pathology, manifesting as a progressive asymmetric akinetic-rigid, poorly levodopa-responsive parkinsonism, with cerebral cortical dysfunction. CBD can manifest as several clinical phenotypes, and similarly, CBS can also have a pathologic diagnosis other than CBD. This chapter discusses the clinical manifestations of pathologically confirmed CBD cases, the current diagnostic criteria, as well as the pathologic and neuroimaging findings of CBD/CBS. At present, therapeutic options for CBD remain symptomatic. Further research is needed to improve the clinical diagnosis of CBD, as well as studies on disease-modifying therapies for this relentlessly progressive neurodegenerative disorder.",
keywords = "4R-tauopathy, Atypical parkinsonism, Corticobasal degeneration, Corticobasal syndrome, Tauopathy",
author = "Saranza, {Gerard M.} and Whitwell, {Jennifer L.} and Kovacs, {Gabor G.} and Lang, {Anthony E.}",
year = "2019",
doi = "10.1016/bs.irn.2019.10.014",
language = "English (US)",
isbn = "9780128177303",
series = "International Review of Neurobiology",
publisher = "Academic Press Inc.",
pages = "87--136",
editor = "Maria Stamelou and H{\"o}glinger, {G{\"u}nter U.}",
booktitle = "International Review of Neurobiology",

}

TY - CHAP

T1 - Corticobasal degeneration

AU - Saranza, Gerard M.

AU - Whitwell, Jennifer L.

AU - Kovacs, Gabor G.

AU - Lang, Anthony E.

PY - 2019

Y1 - 2019

N2 - Corticobasal degeneration (CBD) is a rare neurodegenerative disease characterized by the predominance of pathological 4 repeat tau deposition in various cell types and anatomical regions. Corticobasal syndrome (CBS) is one of the clinical phenotypes associated with CBD pathology, manifesting as a progressive asymmetric akinetic-rigid, poorly levodopa-responsive parkinsonism, with cerebral cortical dysfunction. CBD can manifest as several clinical phenotypes, and similarly, CBS can also have a pathologic diagnosis other than CBD. This chapter discusses the clinical manifestations of pathologically confirmed CBD cases, the current diagnostic criteria, as well as the pathologic and neuroimaging findings of CBD/CBS. At present, therapeutic options for CBD remain symptomatic. Further research is needed to improve the clinical diagnosis of CBD, as well as studies on disease-modifying therapies for this relentlessly progressive neurodegenerative disorder.

AB - Corticobasal degeneration (CBD) is a rare neurodegenerative disease characterized by the predominance of pathological 4 repeat tau deposition in various cell types and anatomical regions. Corticobasal syndrome (CBS) is one of the clinical phenotypes associated with CBD pathology, manifesting as a progressive asymmetric akinetic-rigid, poorly levodopa-responsive parkinsonism, with cerebral cortical dysfunction. CBD can manifest as several clinical phenotypes, and similarly, CBS can also have a pathologic diagnosis other than CBD. This chapter discusses the clinical manifestations of pathologically confirmed CBD cases, the current diagnostic criteria, as well as the pathologic and neuroimaging findings of CBD/CBS. At present, therapeutic options for CBD remain symptomatic. Further research is needed to improve the clinical diagnosis of CBD, as well as studies on disease-modifying therapies for this relentlessly progressive neurodegenerative disorder.

KW - 4R-tauopathy

KW - Atypical parkinsonism

KW - Corticobasal degeneration

KW - Corticobasal syndrome

KW - Tauopathy

UR - http://www.scopus.com/inward/record.url?scp=85075359805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075359805&partnerID=8YFLogxK

U2 - 10.1016/bs.irn.2019.10.014

DO - 10.1016/bs.irn.2019.10.014

M3 - Chapter

C2 - 31779825

AN - SCOPUS:85075359805

SN - 9780128177303

T3 - International Review of Neurobiology

SP - 87

EP - 136

BT - International Review of Neurobiology

A2 - Stamelou, Maria

A2 - Höglinger, Günter U.

PB - Academic Press Inc.

ER -